UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Scenario planning as communicative action: Lessons from participatory exercises conducted for the Scottish livestock industry

Technological forecasting & social change, 2017-01, Vol.114, p.138-151

2017

Volltextzugriff (PDF)

Immune checkpoint inhibitors as adjuvants: future challenges for pricing and reimbursement

Value in health, 2015-05, Vol.18 (3), p.A219-A219

2015

Volltextzugriff (PDF)

3218 PACEBOM in relapsed/refractory (R/R) lymphoma in the rituximab (R) era

European journal of cancer (1990), 2015-09, Vol.51, p.S655-S655

2015

Volltextzugriff (PDF)

Identification and management of canadian patients with symptoms of statin intolerance: Results from a real-world clinical practice survey

Atherosclerosis, 2016-09, Vol.252, p.e212-e212

2016

Volltextzugriff (PDF)

A Phase II Trial of Integrated Preoperative Radiotherapy and Chemotherapy with Oxaliplatin 5-Fluorouracil and Folinic Acid in Patients with Locally Advanced Rectal Cancer: Trans-Tasman Radiation Oncology Group TROG 09.01

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S21-S22

2014

Volltextzugriff (PDF)

Estimating Healthcare resource use associated with the treatment of Metastatic Melanoma in Eight Countries

Value in health, 2015-05, Vol.18 (3), p.A259-A259

2015

Volltextzugriff (PDF)

3215 Outcome of ABVD chemotherapy in an Australian population of Hodgkin lymphoma (HL)

European journal of cancer (1990), 2015-09, Vol.51, p.S654-S654

2015

Volltextzugriff (PDF)

HTA81 Assessing Evidence Packages of CRISPR Technologies: Will They Meet Payer Needs?

Value in health, 2024-06, Vol.27 (6), p.S259-S259

2024

Volltextzugriff (PDF)

Failing young people? Education and aspirations in a deprived community

Education, citizenship and social justice, 2010-03, Vol.5 (1), p.5-20

2010

Volltextzugriff (PDF)

SA22 Does the Use of Investigator-Choice Comparator Arms in Oncology Clinical Trials Influence Payer Assessments Outcomes?

Value in health, 2024-06, Vol.27 (6), p.S399-S400

2024

Volltextzugriff (PDF)

HTA53 Advances in Science and Challenges at HTA: The Case of CRISPR Technologies

Value in health, 2024-06, Vol.27 (6), p.S254-S254

2024

Volltextzugriff (PDF)

SA12 Investigator Choice Comparator Arms in Oncology Clinical Trials: Implications for HTA/Reimbursement Assessments

Value in health, 2024-06, Vol.27 (6), p.S398-S398

2024

Volltextzugriff (PDF)

P0183 Resection of colorectal cancer metastases in routine practice

European journal of cancer (1990), 2014-05, Vol.50, p.e62-e62

2014

Volltextzugriff (PDF)

EP-1254: Achieving durable local control without surgery in unresectable, metastatic rectal cancer

Radiotherapy and oncology, 2014, Vol.111, p.S73-S73

2014

Volltextzugriff (PDF)

7168 POSTER Health Related Quality of Life (QOL) Assessment In Stage 1 Semlnomatous Germ Cell Tumour Patients Treated With Either Adjuvant Carboplatin Chemotherapy, Adjuvant Radiotherapy or High Intensity Chemotherapy

European journal of cancer (1990), 2011, Vol.47, p.S526-S526

2011

Volltextzugriff (PDF)

PNS191 US Payer Priorities in Evaluation of Clinical and Humanistic Outcomes Evidence

Value in health, 2020-12, Vol.23, p.S673-S673

2020

Volltextzugriff (PDF)

6050 POSTER A 12-week Regimen With Interdigitating FOLFOX Chemotherapy and Pelvic Chemoradiation for Simultaneous Primary and Metastatic Rectal Cancer

European journal of cancer (1990), 2011, Vol.47, p.S406-S406

2011

Volltextzugriff (PDF)

Methodological differences and the appropriate application of oncology value frameworks to assess clinical value

Annals of oncology, 2016-10, Vol.27, p.vi351-vi351

2016

Volltextzugriff (PDF)

HPR25 Current Reimbursement Landscape for Re-Treatment with Anti-PD-(L)1 Agents after Treatment in Early-Stage Cancers: A Payer Survey

Value in health, 2024-06, Vol.27 (6), p.S199-S200

2024

Volltextzugriff (PDF)

HTA80 Impact of Restricted EU Market Access Decisions on Patient Access To Medicines in Multiple Myeloma

Value in health, 2024-06, Vol.27 (6), p.S259-S259

2024

Volltextzugriff (PDF)

HTA18 Impact of The Use of Cost-Effectiveness Analysis (CEA) on Patient Access to Medicines: A Comparison of CEA vs Non-CEA Markets

Value in health, 2022-12, Vol.25 (12), p.S299-S299

2022

Volltextzugriff (PDF)

Results From VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC)

European journal of cancer (1990), 2011, Vol.47, p.5-5

2011

Volltextzugriff (PDF)

PCN474 MAPPING PATIENT INVOLVEMENT IN NICE APPRAISALS OF ONCOLOGY PRODUCTS

Value in health, 2019-11, Vol.22, p.S529

2019

Volltextzugriff (PDF)

Understanding Methodological Differences Between and The Appropriate Application of Oncology Value Frameworks in Healthcare Decision-Making

Value in health, 2016-11, Vol.19 (7), p.A743-A743

2016

Volltextzugriff (PDF)

PCN194 - Understanding Methodological Differences Between and The Appropriate Application of Oncology Value Frameworks in Healthcare Decision-Making

Value in health, 2016-11, Vol.19 (7), p.A743-A743

2016

Volltextzugriff (PDF)

1 – 25 von 447

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(372)
Mit Volltextzugriff
(360)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(39)
Social Sciences
(34)
Male
(25)
Internal Medicine
(24)
Geography
(18)
Female
(17)
Adult
(15)
Biological And Medical Sciences
(15)
Physiology
(14)
Aged
(13)
Middle Aged
(13)
Blood
(11)
Correspondence
(10)
Medical Sciences
(10)
Hematology, Oncology And Palliative Medicine
(9)
Dentistry
(8)
Exact Sciences And Technology
(8)
Business & Economics
(7)
Children
(7)
Education & Educational Research
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Scenario planning as communicative action: Lessons from participatory exercises conducted for the Scottish livestock industry

Immune checkpoint inhibitors as adjuvants: future challenges for pricing and reimbursement

3218 PACEBOM in relapsed/refractory (R/R) lymphoma in the rituximab (R) era

Identification and management of canadian patients with symptoms of statin intolerance: Results from a real-world clinical practice survey

A Phase II Trial of Integrated Preoperative Radiotherapy and Chemotherapy with Oxaliplatin 5-Fluorouracil and Folinic Acid in Patients with Locally Advanced Rectal Cancer: Trans-Tasman Radiation Oncology Group TROG 09.01

Estimating Healthcare resource use associated with the treatment of Metastatic Melanoma in Eight Countries

3215 Outcome of ABVD chemotherapy in an Australian population of Hodgkin lymphoma (HL)

HTA81 Assessing Evidence Packages of CRISPR Technologies: Will They Meet Payer Needs?

Failing young people? Education and aspirations in a deprived community

SA22 Does the Use of Investigator-Choice Comparator Arms in Oncology Clinical Trials Influence Payer Assessments Outcomes?

HTA53 Advances in Science and Challenges at HTA: The Case of CRISPR Technologies

SA12 Investigator Choice Comparator Arms in Oncology Clinical Trials: Implications for HTA/Reimbursement Assessments

P0183 Resection of colorectal cancer metastases in routine practice

EP-1254: Achieving durable local control without surgery in unresectable, metastatic rectal cancer

7168 POSTER Health Related Quality of Life (QOL) Assessment In Stage 1 Semlnomatous Germ Cell Tumour Patients Treated With Either Adjuvant Carboplatin Chemotherapy, Adjuvant Radiotherapy or High Intensity Chemotherapy

PNS191 US Payer Priorities in Evaluation of Clinical and Humanistic Outcomes Evidence

6050 POSTER A 12-week Regimen With Interdigitating FOLFOX Chemotherapy and Pelvic Chemoradiation for Simultaneous Primary and Metastatic Rectal Cancer

Methodological differences and the appropriate application of oncology value frameworks to assess clinical value

HPR25 Current Reimbursement Landscape for Re-Treatment with Anti-PD-(L)1 Agents after Treatment in Early-Stage Cancers: A Payer Survey

HTA80 Impact of Restricted EU Market Access Decisions on Patient Access To Medicines in Multiple Myeloma

HTA18 Impact of The Use of Cost-Effectiveness Analysis (CEA) on Patient Access to Medicines: A Comparison of CEA vs Non-CEA Markets

Results From VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC)

PCN474 MAPPING PATIENT INVOLVEMENT IN NICE APPRAISALS OF ONCOLOGY PRODUCTS

Understanding Methodological Differences Between and The Appropriate Application of Oncology Value Frameworks in Healthcare Decision-Making

PCN194 - Understanding Methodological Differences Between and The Appropriate Application of Oncology Value Frameworks in Healthcare Decision-Making

Aktive Filter

Suchergebnisse filtern